Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Nano Lett ; 11(4): 1760-5, 2011 Apr 13.
Article in English | MEDLINE | ID: mdl-21410242

ABSTRACT

Silver nanoparticle arrays placed on top of a high-refractive index substrate enhance the coupling of light into the substrate over a broad spectral range. We perform a systematic numerical and experimental study of the light incoupling by arrays of Ag nanoparticle arrays in order to achieve the best impedance matching between light propagating in air and in the substrate. We identify the parameters that determine the incoupling efficiency, including the effect of Fano resonances in the scattering, interparticle coupling, as well as resonance shifts due to variations in the near-field coupling to the substrate and spacer layer. The optimal configuration studied is a square array of 200 nm wide, 125 nm high spheroidal Ag particles, at a pitch of 450 nm on a 50 nm thick Si(3)N(4) spacer layer on a Si substrate. When integrated over the AM1.5 solar spectral range from 300 to 1100 nm, this particle array shows 50% enhanced incoupling compared to a bare Si wafer, 8% higher than a standard interference antireflection coating. Experimental data show that the enhancement occurs mostly in the spectral range near the Si band gap. This study opens new perspectives for antireflection coating applications in optical devices and for light management in Si solar cells.


Subject(s)
Nanostructures/chemistry , Nanostructures/ultrastructure , Refractometry/instrumentation , Silver/chemistry , Surface Plasmon Resonance/instrumentation , Electric Impedance , Equipment Design , Equipment Failure Analysis , Light , Materials Testing , Scattering, Radiation
2.
Acta Cardiol ; 45(1): 57-64, 1990.
Article in English | MEDLINE | ID: mdl-2316304

ABSTRACT

In a pilot study the effect of a bolus dose of amrinone intravenously (IV), 0.5 or 1 mg/kg body weight, in 10 patients with chronic obstructive lung disease and cor pulmonale was evaluated. We found that the higher dose of 1.0 mg/kg IV significantly (P less than 0.05) decreased the mean pulmonary artery pressure and pulmonary wedge pressure without significant changes in cardiac output, in systemic blood pressure or in arterial blood gas values. No adverse effects were recorded in any of the patients.


Subject(s)
Amrinone/therapeutic use , Lung Diseases, Obstructive/drug therapy , Pulmonary Heart Disease/drug therapy , Aged , Amrinone/administration & dosage , Cardiac Output/drug effects , Dose-Response Relationship, Drug , Female , Humans , Lung Diseases, Obstructive/complications , Male , Middle Aged , Pilot Projects , Pulmonary Heart Disease/etiology , Pulmonary Wedge Pressure/drug effects , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...